Skip to main content Skip to main content
Go to homepage

A study evaluating safety and efficacy of Debio 4326

A study evaluating the safety and efficacy of Debio 4326 in treating precocious puberty in children receiving gonadotropin-releasing hormone agonist


Please view the study at for complete information.

Interested in participating?
We are currently recruiting
Study Sponsor:

Debiopharm International S.A

Full IRB Study Title:
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Naveen Uli, MD -  Phone: 330-543-3276; email:
JoAnn Katz, BSN – Phone: 330-543-0690; email:

Lead Investigator
Naveen Uli, MD

Medical Director, Center for Diabetes and Endocrinology; Pediatric Endocrinologist

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.